Sedative effects and serum drug concentrations of oxymorphone and metabolites after subcutaneous administration of a liposome-encapsulated formulation in dogs

Journal of Veterinary Pharmacology and Therapeutics

Volumn 27, Issue 5, 2004, Pages 369-372

  Smith, Lesley J ^a   Krugner Higby, L ^a   Trepanier, L A ^a   Flaska, D E ^a   Joers, V ^a   Heath, T D ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTORPHANOL; CODEINE; DRUG METABOLITE; FENTANYL; LIPOSOME; MORPHINE; OPIATE; OXYCODONE; OXYMORPHONE;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; ARTICLE; BRADYCARDIA; BREATHING RATE; CHRONIC PAIN; CONSTIPATION; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG FORMULATION; ENCAPSULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART RATE; HYDROPHOBICITY; LIPOPHILICITY; MALE; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RECTUM TEMPERATURE; RESPIRATION DEPRESSION; SCORING SYSTEM; SEDATION; SUSTAINED RELEASE PREPARATION; TECHNIQUE; URINE RETENTION; VETERINARY MEDICINE;

ANALGESICS, OPIOID; ANIMALS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; FEMALE; HEART RATE; HYPNOTICS AND SEDATIVES; INJECTIONS, SUBCUTANEOUS; LIPOSOMES; MALE; OXYMORPHONE; RESPIRATION;

ANIMALIA; CANIS FAMILIARIS;

EID: 8344257237     PISSN: 01407783     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2004.00582.x     Document Type: Article

References (19)

1. Cone, E.J., Darwin, W.D., Buchwald, W.F. & Gorodetzky, C.E. (1983) Oxymorphone metabolism and urinary excretion in human, rat, guinea pig, rabbit, and dog. Drug Metabolism and Disposition, 11, 446-450.
2. Dohoo, S. (1997) Steady-state pharmacokinetics of oral sustained release morphine sulphate in dogs. Journal of Veterinary Pharmacology and Therapeutics, 20, 129-133.
3. Egger, C.M., Duke, T., Archer, J. & Cribb, P.H. (1998) Comparison of plasma fentanyl concentrations by using three transdermal fentanyl patch sizes in dogs. Veterinary Surgery, 27, 159-166.
4. Gourlay, G.K., Cherry, D.A., Onley, M.M., Tordoff, S.G., Conn, D.A., Hood, G.M. & Plummer, J.L. (1997) Pharmacokinetics and pharmacodynamics of twenty-four-hourly Kapanol compared to twelve-hourly MS Contin in the treatment of severe cancer pain. Pain, 69, 295-302.
5. Hardwick, W.E., King, W.D. & Palmisano, P.A. (1997) Respiratory depression in a child unintentionally exposed to transdermal fentanyl patch. Southern Medical Journal, 90, 962-964.
6. Howell, S.B. (2001) Clinical applications of a novel sustained-release injectable drug delivery system: Depofoam™ technology. Cancer Journal, 7, 219-227.
7. Kirby, C.J. & Gregoriadis, G. (1984) A simple procedure for preparing liposomes capable of high encapsulation efficiency under mild conditions. In Liposome Technology. Vol. I. Ed. Gregoriadis, G. pp. 19-27, CRC Press, Boca Raton, FL.
8. Krugner-Higby, L., Smith, L.J. & Heath, T. (2002) Liposome-encapsulated oxymorphone hydrochloride for long-term analgesia. United States Patent Application 20030157162: Krugner-Higby, L., Heath, T.D. & Smith, L.J.: Wisconsin Alumnae Research Foundation, Madison, WI 53706, USA.
9. Krugner-Higby, L., Smith, L.J., Clark, M., Heath, T.D., Dahly, E., Schiffman, B., Hubbard-VanStelle, S., Ney, D. & Wendland, A. (2003) Liposome-encapsulated oxymorphone hydrochloride provides prolonged relief of post-surgical visceral pain in rats. Comparative Medicine, 53, 270-280.
10. Kyles, A.E., Papich, M. & Hardie, E.M. (1996) Disposition of transdermally administered fentanyl in dogs. American Journal of Veterinary Research, 57, 715-719.
11. Purucker, M. & Swann, W. (2000) Potential for duragesic patch abuse. Annals of Emergency Medicine, 35, 314
12. Pascoe, P.J. (2000a) Opioid analgesics. In Pain Management: Veterinary Clinics of North America, Small Animal Practice Ed. Matthews, K.A. pp. 757-772. WB Saunders Co., Philadelphia, PA.
13. Pascoe, P.J. (2000b) Perioperative pain management. In Management of Pain: Veterinary Clinics of North America, Small Animal Practice Ed. Matthews, K.A. pp. 917-933. WB Saunders Co., Philadelphia, PA.
14. Passik, S.D. (2001) Responding rationally to recent report of abuse/diversion of oxycontin. Journal of Pain and Symptom Management, 21, 359.
15. Smith, L.J., Yu, J.K.-A., Bjorling, D.E. & Waller, K. (2001) Effects of hydromorphone or oxymorphone, with or without acepromazine, on preanesthetic sedation, physiologic values, and histamine release in dogs. Journal of the American Veterinary Medical Association, 218, 1101-1105.
16. Smith, L.J., Krugner-Higby, L., Clark, M., Wendland, A. & Heath, T.D. (2003) Liposome-encapsulated oxymorphone provides prolonged analgesia in an animal model of neuropathic pain. Comparative Medicine, 53, 280-288.
17. Wasserman, S. (2001) States respond to growing abuse of painkiller. State Legislatures, 27, 33-34.
18. Yaksh, T.L., Provencher, J.C., Rathbun, M.L. & Kohn, F.R. (1999) Pharmacokinetics and efficacy of epidurally delivered sustained-release encapsulated morphine in dogs. Anesthesiology, 90, 1402-1412.
19. Yaksh, T.L., Provencher, J.C., Rathbun, M.L., Myers, R.R., Powell, H., Richter, P. & Kohn, F.R. (2000) Safety assessment of encapsulated morphine delivered epidurally in a sustained-release multivesicular liposome preparation in dogs. Drug Delivery, 7, 27-36.